Drug Combination Beneficial for Smoldering Multiple Myeloma

Abstract Patients with high-risk smoldering multiple myeloma who received lenalidomide and dexamethasone for 9 months, followed by lenalidomide alone for an additional 15 months, demonstrated significantly improved overall and progression-free survival compared with patients who received no therapy.